News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Genetown
pSivida Corp: Enrollment complete in BrachySil(TM) Dose Ranging Study
March 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PSI), a leading drug delivery company today announced the completion of enrollment of the BrachySil™ (P32 BioSilicon™) dose ranging clinical trial.
Twitter
LinkedIn
Facebook
Email
Print
MORE ON THIS TOPIC
Job Trends
Massachusetts’ Life Sciences Job Growth Slows, but 10-Year Outlook Remains Strong: Report
June 12, 2024
·
4 min read
·
Angela Gabriel
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
·
4 min read
·
Lorenzo Soliman
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
·
3 min read
·
Greg Slabodkin
FDA
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
May 7, 2024
·
4 min read
·
Tyler Patchen
